SARS-CoV-2 spreads through cell-to-cell transmission
Significance
It is currently unknown if SARS-CoV-2 can spread through cell–cell contacts, and if so, the underlying mechanisms and implications. In this work, we show, by using lentiviral pseudotyped virus, that the spike protein of SARS-CoV-2 mediates the viral cell-to-cell transmission, with an efficiency higher than that of SARS-CoV. We also find that cell–cell fusion contributes to cell-to-cell transmission, yet ACE2 is not absolutely required. While the authentic variants of concern (VOCs) B.1.1.7 (alpha) and B.1.351 (beta) differ in cell-free infectivity from wild type and from each other, these VOCs have similar cell-to-cell transmission capability and exhibit differential sensitivity to neutralization by vaccinee sera. Results from our study will contribute to a better understanding of SARS-CoV-2 spread and pathogenesis.
Top-30
Journals
2
4
6
8
10
12
|
|
Viruses
11 publications, 6.71%
|
|
Journal of Virology
7 publications, 4.27%
|
|
iScience
6 publications, 3.66%
|
|
Journal of Medical Virology
5 publications, 3.05%
|
|
International Journal of Molecular Sciences
4 publications, 2.44%
|
|
Nature Communications
4 publications, 2.44%
|
|
Emerging Microbes & Infections
4 publications, 2.44%
|
|
Proceedings of the National Academy of Sciences of the United States of America
4 publications, 2.44%
|
|
Frontiers in Immunology
4 publications, 2.44%
|
|
mBio
3 publications, 1.83%
|
|
Vaccines
2 publications, 1.22%
|
|
Biomedicines
2 publications, 1.22%
|
|
Biomedicine and Pharmacotherapy
2 publications, 1.22%
|
|
PLoS Pathogens
2 publications, 1.22%
|
|
MedComm
2 publications, 1.22%
|
|
Science advances
2 publications, 1.22%
|
|
PLoS Computational Biology
2 publications, 1.22%
|
|
Advanced Science
2 publications, 1.22%
|
|
Virology
2 publications, 1.22%
|
|
Journal of Biomedical Science
2 publications, 1.22%
|
|
Antiviral Research
2 publications, 1.22%
|
|
Scientific Reports
2 publications, 1.22%
|
|
Vaccine
2 publications, 1.22%
|
|
Cell Death and Disease
1 publication, 0.61%
|
|
PLoS Biology
1 publication, 0.61%
|
|
Journal of Clinical Investigation
1 publication, 0.61%
|
|
Archivum Immunologiae et Therapiae Experimentalis
1 publication, 0.61%
|
|
Cells
1 publication, 0.61%
|
|
Virulence
1 publication, 0.61%
|
|
2
4
6
8
10
12
|
Publishers
5
10
15
20
25
30
|
|
Elsevier
29 publications, 17.68%
|
|
Springer Nature
27 publications, 16.46%
|
|
MDPI
25 publications, 15.24%
|
|
Wiley
14 publications, 8.54%
|
|
Cold Spring Harbor Laboratory
14 publications, 8.54%
|
|
American Society for Microbiology
11 publications, 6.71%
|
|
Frontiers Media S.A.
7 publications, 4.27%
|
|
Public Library of Science (PLoS)
6 publications, 3.66%
|
|
Taylor & Francis
5 publications, 3.05%
|
|
Proceedings of the National Academy of Sciences (PNAS)
4 publications, 2.44%
|
|
American Association for the Advancement of Science (AAAS)
3 publications, 1.83%
|
|
American Society for Clinical Investigation
2 publications, 1.22%
|
|
American Chemical Society (ACS)
1 publication, 0.61%
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.61%
|
|
American Thoracic Society
1 publication, 0.61%
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.61%
|
|
Eco-Vector LLC
1 publication, 0.61%
|
|
European Molecular Biology Organization
1 publication, 0.61%
|
|
The Royal Society
1 publication, 0.61%
|
|
Research Square Platform LLC
1 publication, 0.61%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.61%
|
|
S. Karger AG
1 publication, 0.61%
|
|
FSPSI SCFHHRP
1 publication, 0.61%
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.